A newly developed radiotracer can generate high quality and readily interpretable images of cardiac amyloidosis, a condition referred to as the 'Alzheimer's disease of the heart.' As the first amyloid ...

Bayer, a leading company in key areas of radiology and cardiology, and Attralus, Inc. (Attralus), a clinical stage biopharmaceutical company focused on developing medicines and diagnostics for ...

Bayer, looking to bolster its position in both imaging and cardiac medicine, struck a deal to snap up two experimental imaging agents and thereby enter the diagnostic tracers development space. | ...

Bayer to acquire AT-01 & AT-05, investigational molecular imaging agents for the diagnosis of cardiac amyloidosis from Attralus: Berlin, Germany Wednesday, January 14, 2026, 11:00 ...

NAPLES, Fla., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines and diagnostics to improve the lives of patients with ...

FRANKFORD (WPVI) -- Heart failure often follows heart attacks, diabetes, or high blood pressure. However, a very different cause is being identified more and more. For Elsie McGruder, the first sign ...

Please provide your email address to receive an email when new articles are posted on . An AI model accurately distinguished cardiac amyloidosis from other phenotypic mimics. The model also showed ...

A quiet revolution in care is helping patients with cardiac amyloidosis, a form of heart failure that long stumped doctors. By Simar Bajaj When James Hicks, 75, was diagnosed with heart failure, it ...

Figure 1. Representative whole body planar images of 99m Tc-p5+14 of healthy subjects and, with SPECT/CT images, of a patient with ATTRv cardiac amyloidosis at 1 h post injection showing no uptake in ...